507 related articles for article (PubMed ID: 31196453)
1. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
Charytan DM; Sabatine MS; Pedersen TR; Im K; Park JG; Pineda AL; Wasserman SM; Deedwania P; Olsson AG; Sever PS; Keech AC; Giugliano RP;
J Am Coll Cardiol; 2019 Jun; 73(23):2961-2970. PubMed ID: 31196453
[TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
3. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
5. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
[TBL] [Abstract][Full Text] [Related]
7. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Murphy SA; Pedersen TR; Gaciong ZA; Ceska R; Ezhov MV; Connolly DL; Jukema JW; Toth K; Tikkanen MJ; Im K; Wiviott SD; Kurtz CE; Honarpour N; Giugliano RP; Keech AC; Sever PS; Sabatine MS
JAMA Cardiol; 2019 Jul; 4(7):613-619. PubMed ID: 31116355
[TBL] [Abstract][Full Text] [Related]
8. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
[TBL] [Abstract][Full Text] [Related]
10. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS;
Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP; Pedersen TR; Park JG; De Ferrari GM; Gaciong ZA; Ceska R; Toth K; Gouni-Berthold I; Lopez-Miranda J; Schiele F; Mach F; Ott BR; Kanevsky E; Pineda AL; Somaratne R; Wasserman SM; Keech AC; Sever PS; Sabatine MS;
Lancet; 2017 Oct; 390(10106):1962-1971. PubMed ID: 28859947
[TBL] [Abstract][Full Text] [Related]
13. Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Marston NA; Kamanu FK; Nordio F; Gurmu Y; Roselli C; Sever PS; Pedersen TR; Keech AC; Wang H; Lira Pineda A; Giugliano RP; Lubitz SA; Ellinor PT; Sabatine MS; Ruff CT
Circulation; 2020 Feb; 141(8):616-623. PubMed ID: 31707849
[TBL] [Abstract][Full Text] [Related]
14. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Gencer B; Mach F; Murphy SA; De Ferrari GM; Huber K; Lewis BS; Ferreira J; Kurtz CE; Wang H; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2020 Aug; 5(8):952-957. PubMed ID: 32432684
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
Bohula EA; Marston NA; Ruzza A; Murphy SA; De Ferrari GM; Diaz R; Leiter LA; Elliott-Davey M; Wang H; Bhatia AK; Giugliano RP; Sabatine MS
Am Heart J; 2024 Mar; 269():179-190. PubMed ID: 38160917
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
[TBL] [Abstract][Full Text] [Related]
19. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Marston NA; Gurmu Y; Melloni GEM; Bonaca M; Gencer B; Sever PS; Pedersen TR; Keech AC; Roselli C; Lubitz SA; Ellinor PT; O'Donoghue ML; Giugliano RP; Ruff CT; Sabatine MS
Circulation; 2020 May; 141(20):1600-1607. PubMed ID: 32223429
[TBL] [Abstract][Full Text] [Related]
20. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.
Oyama K; Furtado RHM; Fagundes A; Zelniker TA; Tang M; Kuder J; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
J Am Coll Cardiol; 2021 Jan; 77(3):259-267. PubMed ID: 33197560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
